期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

马来酸罗格列酮对2型糖尿病患者糖脂代谢、胰岛素抵抗及血清炎症因子的影响 被引量：27

The effects of rosiglitazone on lipid and glucose metabolism,insulin resistance and inflammatory factors in type 2 diabetic patients
下载PDF
导出
摘要 与磺脲联合二甲双胍治疗39例2型糖尿病12周相比，43例加用马来酸罗格列酮治疗12周者血糖与血脂谱改善明显，胰岛素敏感性增加，C-RP水平降低（P〈0．05～0．01）。 Compared with the 39 cases with T2DM treated by SU＋metformin, the 43 T2DM patients treated by SU＋metformin＋ rosiglitazone for 12 weeks had the improved glycemic and lipid profile controls, increased insulin sensitivity, and decreased CRP level（all P〈0.05 or 〈0.01）.
作者 黄斌 罗琳 韩文群 谢雪 罗先策 魏东
机构地区 成都市第二人民医院内分泌科
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2006年第1期9-10,共2页 Chinese Journal of Diabetes
关键词 罗格列酮 胰岛素抵抗 C反应蛋白 肿瘤坏死因子 Rosiglitazone Insulin resistance C-reactive protein Tumor necrosis factor
分类号 R587.1 [医药卫生—内分泌] R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献5

  • 1朱禧星,潘长玉,李光伟,史虹莉,田慧,杨文英,姜晶,孙晓春,C.DAVIES,王梅,周永浩.磺酰脲类药物合用马来酸罗格列酮治疗2型糖尿病的有效性和安全性观察——随机、双盲、对照、平行、多中心临床试验[J].中华内分泌代谢杂志,2003,19(3). 被引量：36
  • 2Wolffrenbuttel BHR,Gomist R,Squatrito S,et al.Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabetic Med,2000,17:40-47.
  • 3Pradhan A D,Manson J E,Nader R,et al.C-reactive protein,interleukin-6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286:327-334.
  • 4Pickup JC,Crook MA.Is type Ⅱ diabetes mellitus a disease of innate immune system? Diabetologia,1998,41:1241-1248.
  • 5Grigsby RJ,Dobrowsky RT.Inhibition of ceramide productionreverses TNF-induced insulin resistance.Biochem Biophys Res Commun,2001,287:1121 1124.

二级参考文献19

  • 1Whiteomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs, 1995,4 : 1299-1309.
  • 2lmura H. A novel antidiabetic drug, troglitazone-reason for hope and concern. New Engl J Med, 1998,338:908-909.
  • 3Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2.diabetic patients. Diabetic Med, 2000,17:40-47.
  • 4Narayan KMV, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract, 2000,50 ( Suppl 2 ) : S77-S84.
  • 5Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, mefformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies ( UKPDS 49), JAMA1999,281:2005-2012.
  • 6Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes, 2001,50 : A542.
  • 7Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev, 2002,18 : 127-134.
  • 8Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British lndo-Asian patients. Diabetic Med, 2001,18 :A40.
  • 9Dogterum P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythrupoiesis or premature red cell destruction. Diabetes, 1999,48 :A98.
  • 10Samraj GP, Kuritzky L, Quillen DM. Improving management of type 2 diabetes mellitus : 5. Thiazolidinediones. Hosp Pract, 2000,35 : 123-124.

共引文献35

同被引文献256

引证文献27

二级引证文献53

中国糖尿病杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部